For most women under 60 who start within 10 years of menopause, hormone replacement therapy (HRT) is considered safe and the benefits generally outweigh the risks. That’s the current position of major medical societies, including the North American Menopause Society. But “safe” isn’t a simple yes or no. The answer depends on your age, when you start, which type you use, how it’s delivered, and your personal health history.
The Timing Window That Changes Everything
The single biggest factor in HRT safety is when you start it relative to menopause. Women who begin HRT before age 60, or within 10 years of their last period, appear to get cardiovascular protection rather than harm. Meta-analyses comparing younger and older initiators found significant differences in death rates and heart events, with younger starters seeing reductions in both.
Starting HRT after age 65 is a different picture. In the Women’s Health Initiative Memory Study, women randomized to combined hormone therapy at that age saw an additional 23 cases of dementia per 10,000 person-years. This doesn’t mean HRT causes dementia across the board. It means the aging cardiovascular system responds differently to hormones than a younger one does. The timing window matters more than almost any other variable.
Breast Cancer Risk in Real Numbers
Breast cancer is the risk most women worry about, and the actual numbers are more modest than many assume. A large meta-analysis published in The Lancet, drawing on worldwide data, calculated the 20-year breast cancer risk for women starting HRT at age 50 and using it for five years.
- Combined HRT with daily progestogen: Risk rose from 6.3% to 8.3%, an absolute increase of 2 in 100 women (1 in 50 users).
- Combined HRT with intermittent progestogen: Risk rose from 6.3% to 7.7%, an absolute increase of 1.4 in 100 women (1 in 70 users).
- Estrogen-only HRT: Risk rose from 6.3% to 6.8%, an absolute increase of 0.5 in 100 women (1 in 200 users).
Estrogen-only therapy carries a much smaller breast cancer signal than combined therapy. However, estrogen alone is only safe for women who’ve had a hysterectomy, because unopposed estrogen stimulates the uterine lining and raises the risk of endometrial cancer. For women with a uterus, adding a progestogen is essential protection. Studies show the progestogen needs to be given for at least 10 days per cycle to effectively neutralize endometrial cancer risk. When given for fewer than 10 days monthly, a meaningful increase in endometrial cancer persists.
Blood Clot Risk Depends on Delivery Method
One of the clearest safety distinctions in HRT is how you take it. A large study using UK medical databases found that oral HRT (pills) increased the risk of venous blood clots by about 58% compared to non-users. Transdermal HRT, meaning patches or gels absorbed through the skin, showed no increased clot risk at all.
Compared head to head, oral HRT carried a 70% higher clot risk than transdermal. This is because estrogen swallowed as a pill passes through the liver first, triggering clotting proteins. Estrogen absorbed through the skin bypasses the liver entirely. For women with existing clot risk factors, including obesity, a history of blood clots, or clotting disorders, transdermal delivery is the safer choice and is increasingly what clinicians recommend as a default.
Effects on Metabolism and Insulin
Menopause shifts fat storage toward the midsection and changes how the body handles blood sugar. You might expect HRT to reverse those changes, but the metabolic picture is mixed. A randomized, placebo-controlled trial tracked postmenopausal women for two years and found no difference in belly fat, total body fat, or weight between HRT users and the placebo group.
What did change was insulin sensitivity. Women on combined HRT experienced a 17% drop in insulin sensitivity by six months, and that reduction persisted through two years of treatment. The effect was entirely reversible: one year after stopping HRT, insulin sensitivity returned to baseline. This doesn’t mean HRT causes diabetes, but it’s worth knowing about if you already have insulin resistance or are being monitored for blood sugar changes.
Bone Protection
Bone loss accelerates sharply in the years surrounding menopause as estrogen levels drop. Estrogen plays a direct role in maintaining bone density, and HRT is one of the most effective ways to slow that loss. Current guidelines recognize HRT as appropriate for fracture prevention in women at elevated risk, particularly when other therapies aren’t suitable. For many women, the bone benefits are a secondary but meaningful advantage of treatment they’re already taking for hot flashes or other symptoms.
How Long You Can Stay on It
Older advice often suggested stopping HRT after five years. Current guidelines are more flexible. The 2022 NAMS position statement says HRT does not need to be routinely discontinued in women older than 60 or 65. Long-term use may be appropriate for healthy women at low risk of cardiovascular disease and breast cancer who still have persistent symptoms or elevated fracture risk.
That said, NAMS also notes it’s reasonable to try tapering around age 60 and reassessing whether the benefits still justify continuing. The decision is individual. A woman with severe ongoing hot flashes, strong bones, no family history of breast cancer, and low cardiovascular risk is in a very different position than someone with multiple risk factors.
Who Should Not Take HRT
Certain conditions make systemic HRT unsafe. These include a personal history of breast cancer or estrogen-sensitive cancers, a history of blood clots in the legs or lungs, recent heart attack or stroke, active liver disease, and unexplained vaginal bleeding. Women with untreated endometrial thickening or clotting disorders should also avoid it.
Other conditions don’t rule HRT out entirely but require careful evaluation. High blood pressure, diabetes, obesity, migraines, epilepsy, lupus, and a strong family history of breast cancer all need to be weighed in the decision. In some of these cases, transdermal delivery or lower doses may tip the balance toward acceptable risk. The list of absolute contraindications is shorter than many women assume, and a conversation with a clinician familiar with menopause management can clarify where you fall.
Making the Decision Personal
The safety of HRT is not a single answer but a calculation that depends on your symptoms, your health profile, and the specific type and route of therapy. The broad strokes are clear: starting young (relative to menopause), using transdermal delivery, and choosing the lowest effective dose all shift the risk-benefit ratio in your favor. Estrogen-only therapy is safer on several measures but limited to women without a uterus. Combined therapy adds a small but real breast cancer signal that grows with duration of use.
For women in the early years of menopause with significant symptoms, the current evidence supports HRT as a safe and effective option, not something to fear by default. The risks that dominated headlines two decades ago, drawn largely from older women starting hormones long after menopause, don’t apply in the same way to younger, healthier candidates starting treatment at the right time.